Lupus & antiphospholipid syndrome
Long-term outcome of status epilepticus-related to systemic lupus erythematosus: An observational study and a systematic review
Authors' conclusion
Prompt initiation of immune therapy improve SE-SLE outcome, yet optimal therapeutic strategies remain to be determined.
Study context
- Population
- Patients with status epilepticus related to SLE (SE-SLE)8 hospital cases + 32 from review
- Participants
- 40 patients
- Outcome
- Long-term outcome of SE-SLE in correlation with electro-clinical characteristics, imaging and underlying etiology
Methodological detailssingle tertiary care hospital case series pooled with systematic review cases
- Single tertiary care hospital case series pooled with systematic review cases
Pooled result
As reported in the abstract
Long-term outcomes of SE-SLE
- One-year mortality
- 12.5%
- Recurrent SE-SLE
- 25.0%
- Poor functional outcome
- 55.0%
- Cognitive impairment
- 47.5%
- Seizure freedom
- 60.0%
- Median time to cessation of SE-SLE seizure activity after aggressive therapy
- 14 days
Further pooled results
Seizure freedom and time to cessation of seizure activity after aggressive therapy
- Seizure freedom
- 60.0%
- Median time to cessation of SE-SLE seizure activity after aggressive therapy
- 14 days
Etiology of SE-SLE
- Cases of unclear etiology
- 17.5%
- No specific neuroimaging or laboratory abnormalities allowed early SE-SLE diagnosis
Convulsive SE-SLE
- Occurred with heightened global lupus disease activity and increased cortical and subcortical brain lesion burden, mostly frontal and temporal
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Long-term outcome of status epilepticus-related to systemic lupus erythematosus: An observational study and a systematic review. Semin Arthritis Rheum. Published 10 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →